BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:40 PM
 | 
Jul 06, 2007
 |  BC Extra  |  Clinical News

Johnson & Johnson's etravirine meets HIV endpoints

JNJ said data from two ongoing Phase III trials of etravirine ( TMC125) showed significantly more treatment-experienced HIV-1 patients reached an undetectable viral load with etravirine than placebo. In...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >